Taken together, our work indicates that ProRS inhibition is a novel conduit to regulating transcription and mRNA translation of proto-oncogenic factors in MM and subsequent survival, and accordingly represents a novel therapeutic target of interest. This evidence concerns the gene PARS2 and Miyoshi myopathy.